The diluted thrombin time, ecarin clotting time, activated partial thromboplastin time, thrombin time, and activated clotting time returned to baseline. In healthy subjects aged 45 to 64 years, the plasma concentrations of unbound dabigatran were decreased to the lower limit of quantification immediately after administration of idarucizumab 5 g. The remaining part of the dose is assumed to be eliminated via protein catabolism, mainly in the kidney. Approximately 32% of the dose is recovered in the urine within a collection period of 6 hours and less than 1% in the following 18 hours. Idarucizumab is rapidly eliminated with an initial half-life of 47 minutes and a terminal half-life of 10.3 hours. Idarucizumab undergoes biodegradation of the antibody to smaller peptides or amino acids which are then reabsorbed and incorporated in the general protein synthesis. It exhibits limited extravascular distribution and follows multiphasic disposition kinetics. You may report side effects to FDA at 1-80.Idarucizumab is administered intravenously. Call your doctor for medical advice about side effects. This is not a complete list of side effects and others may occur. pain, swelling, warmth, or redness in one or both legs.Īfter you receive idarucizumab, tell your caregivers right away if you have any bleeding that will not stop.chest pain, wheezing, coughing up blood or.
0 kommentar(er)
